NXD 3109

Drug Profile

NXD 3109

Alternative Names: NXD-3109; Spheron targeting agents

Latest Information Update: 18 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nymox Pharmaceutical Corporation
  • Class Antidementias
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 25 Aug 2004 This compound is still in active development
  • 02 Oct 2001 Preclinical development for Alzheimer's disease in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top